Boston Scientific (BSX) to Buy Residual Shares of Millipede
Following its purchase of a portion of Milipede earlier in 2018, Boston Scientific BSX has been exercising its option to buy the remaining stakes of this privately-held developer of IRIS Transcatheter Annuloplasty Ring System for the treatment of severe mitral regurgitation (MR). This decision comes close on the heels of the recent successful completion of a first-in-human clinical study.The deal is expected to close in the first quarter of 2019, subject to customary closing conditions. Notably, in January 2018, Boston Scientific purchased $90 million of existing and newly-issued Millipede shares […]